GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adimmune Corp (TPE:4142) » Definitions » Institutional Ownership

Adimmune (TPE:4142) Institutional Ownership : 4.14% (As of Apr. 18, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Adimmune Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Adimmune's institutional ownership is 4.14%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Adimmune's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Adimmune's Float Percentage Of Total Shares Outstanding is 0.00%.


Adimmune Institutional Ownership Historical Data

The historical data trend for Adimmune's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adimmune Institutional Ownership Chart

Adimmune Historical Data

The historical data trend for Adimmune can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 5.55 5.69 5.79 5.61 5.62 4.19 3.94 4.04 4.13 4.14

Adimmune Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Adimmune Business Description

Traded in Other Exchanges
N/A
Address
Tanxing Road, No. 3, Sector 1, Tanzi District, Taichung, TWN, 427003
Adimmune Corp is a Taiwan-based company. It is engaged in the development, manufacture, and distribution of vaccines and other biological products. Its pipeline consists of products like AdimFlu-S (QIS) which is a vaccine intended for use in the prevention of influenza, and TetraFlu among others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the USA, China, and other regions.

Adimmune Headlines

No Headlines